Alto Neuroscience (ANRO) Expected to Announce Earnings on Wednesday

Posted by Geri Gentry on May 12th, 2026

Alto Neuroscience (NYSE:ANRO – Get Free Report) will likely be releasing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Alto Neuroscience to post earnings of ($0.56) per share for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 21, 2026 at 9:30 AM ET.

Alto Neuroscience (NYSE:ANRO – Get Free Report) last posted its quarterly earnings data on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. On average, analysts expect Alto Neuroscience to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Alto Neuroscience Stock Performance

NYSE ANRO opened at $24.44 on Tuesday. The company has a quick ratio of 15.69, a current ratio of 15.69 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $780.79 million, a P/E ratio of -11.21 and a beta of 1.62. Alto Neuroscience has a 12-month low of $2.15 and a 12-month high of $28.44. The firm has a 50-day moving average price of $22.99 and a two-hundred day moving average price of $18.19.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Bank of America assumed coverage on shares of Alto Neuroscience in a report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price objective for the company. Weiss Ratings raised shares of Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. JonesTrading cut their price objective on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. Wall Street Zen raised shares of Alto Neuroscience from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $35.00 price objective on shares of Alto Neuroscience in a report on Monday, March 16th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $35.13.

Check Out Our Latest Research Report on ANRO

Hedge Funds Weigh In On Alto Neuroscience

Hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC increased its position in Alto Neuroscience by 20.8% during the 4th quarter. Geode Capital Management LLC now owns 287,435 shares of the company’s stock worth $5,118,000 after purchasing an additional 49,535 shares in the last quarter. State Street Corp increased its position in Alto Neuroscience by 26.6% during the 4th quarter. State Street Corp now owns 130,665 shares of the company’s stock worth $2,326,000 after purchasing an additional 27,480 shares in the last quarter. Renaissance Technologies LLC increased its position in Alto Neuroscience by 28.5% during the 4th quarter. Renaissance Technologies LLC now owns 97,399 shares of the company’s stock worth $1,734,000 after purchasing an additional 21,627 shares in the last quarter. Millennium Management LLC increased its position in Alto Neuroscience by 4.3% during the 3rd quarter. Millennium Management LLC now owns 315,758 shares of the company’s stock worth $1,269,000 after purchasing an additional 12,896 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in Alto Neuroscience during the 4th quarter worth approximately $1,228,000.

Alto Neuroscience Company Profile

(Get Free Report)

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.